WHO prequalifies new ACT

An artesunate-mefloquine fixed-dose combination (ASMQ FDC) has received prequalification status making the malaria drug eligible for tenders receiving funding from international procurement agencies such as UNICEF and the Global Fund to Fight AIDS, Tuberculosis and Malaria. Originally developed by the non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi), ASMQ FDC is now manufactured by India-based Cipla .

According to a press release from DNDi and Cipla, as a single daily dose, ASMQ FDC should increase patient compliance and contribute to reducing the risk of resistance developing.

Read the DNDi – Cipla joint press release.